Patient SELF-management With HemodynamIc Monitoring: Virtual Heart Failure Clinic and Outcomes (the SELFIe-HF Trial): Program

Status: Recruiting
Location: See location...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

To demonstrate that a virtual Heart Failure Clinic (HFC) based on patient self-management using Pulmonary Artery Pressure (PAP) monitoring is superior to usual care of HFC, leads to decreased: hospital admissions for heart failure (HF), emergency department consultation and/or unplanned intravenous heart failure therapy and cardiovascular death, compared to a regular HFC, has low device-related complications and is cost-effective, in New York Heart Association (NYHA) class III and II (requiring diuretics) patients.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Male or female ≥ 18 years old.

• Symptomatic HF (NYHA III) with recent heart failure admission in the previous year (12 months). OR

• Patient with at least one ER visit or unplanned HF clinic requiring iv diuretics within 12 months will be eligible if they have in addition a N-terminal pro-BNP (NT-proBNP) level \> 800pg/ml at screening AND NYHA Class II on diuretics (furosemide ≥ 40mg qd), III or ambulatory IV.

• HF with reduced or preserved EF of at least 3 months duration.

• Minimum technological knowledge either with a smartphone or iPAD for use of the self-management application, including access to internet.

• Anatomical criteria

‣ PA branch diameter between 7 mm - 15 mm

⁃ For BMI \>35, distance from patient's back to target PA\<10cm

Locations
Other Locations
Canada
Montreal Heart Institute
RECRUITING
Montreal
Contact Information
Primary
Anique Ducharme, MD
anique.ducharme@umontreal.ca
5143763330
Backup
Hélène Brown, BSc CCRP
helene.brown@icm-mhi.org
5143763330
Time Frame
Start Date: 2020-05-04
Estimated Completion Date: 2025-12
Participants
Target number of participants: 150
Treatments
No_intervention: Control
Heart failure clinic follow up
Active_comparator: CardioMems
The treatment group will be implanted with a CardioMEMS HF sensor and managed using remote access to hemodynamics compared to a non-implanted control group.
Related Therapeutic Areas
Sponsors
Leads: Montreal Heart Institute

This content was sourced from clinicaltrials.gov